Cargando…

Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study

INTRODUCTION: Real-world evidence on glucagon-like peptide-1 receptor agonist (GLP-1 RAs) usage is emerging in different European countries but is lacking in Italy. This retrospective cohort study aimed to describe the real-world drug utilization patterns in patients initiating GLP-1 RAs for treatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Federici, Marco Orsini, McQuillan, Janette, Biricolti, Giovanni, Losi, Serena, Lebrec, Jeremie, Richards, Catrina, Miglio, Cristiana, Norrbacka, Kirsi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104260/ https://www.ncbi.nlm.nih.gov/pubmed/29525885 http://dx.doi.org/10.1007/s13300-018-0396-2

Ejemplares similares

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2018)

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
por: Divino, Victoria, et al.
Publicado: (2019)

The role of patient preferences in adherence to treatment in chronic disease: a narrative review
por: Losi, Serena, et al.
Publicado: (2021)

Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden
por: Svensson, Ann‐Marie, et al.
Publicado: (2020)

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
por: Zimner Rapuch, Sarah, et al.
Publicado: (2021)

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy
por: Matza, Louis S., et al.
Publicado: (2019)

Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care
por: Orsini Federici, Marco, et al.
Publicado: (2021)

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2021)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes
por: Valentine, William, et al.
Publicado: (2022)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Titanium
por: McQuillan, Alan D, et al.
Publicado: (1959)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
por: Pelle, Maria Chiara, et al.
Publicado: (2023)

Introducing SQL server
por: McQuillan, Mike
Publicado: (2015)

Non-commutative Mori Theory
por: McQuillan, M
Publicado: (2001)

Non-commutative Mori theory
por: McQuillan, M
Publicado: (2000)

Dynamic diophantine approximations and foliations
por: McQuillan, M
Publicado: (1996)

Semi-stable reduction of fiolations
por: McQuillan, M
Publicado: (2005)

Uniform uniformisation
por: McQuillan, M
Publicado: (2005)

The truth inside the comedy
por: McQuillan, Cahal
Publicado: (2021)

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
por: Basson, Mickael, et al.
Publicado: (2017)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
por: Brice, Kira R., et al.
Publicado: (2011)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months
por: Guerci, Bruno, et al.
Publicado: (2022)

Massage Therapy Education Online: Student Satisfaction and Achievement, Part I
por: McQuillan, David James
Publicado: (2010)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014)

Atypical forms of diabetes mellitus in Africans and other non-European ethnic populations in low- and middle-income countries: a systematic literature review
por: Bavuma, Charlotte, et al.
Publicado: (2019)

SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study
por: Graybill, Sky
Publicado: (2019)

The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study
por: Fan, Ying-Chi, et al.
Publicado: (2023)

Roth's theorem for ruled surfaces
por: Gasbarri, C, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_due0idn6plmonst4tkvhajp2hb